Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 334

1.

The importance of CD39, CD43, CD81, and CD95 expression for differentiating B cell lymphoma by flow cytometry.

Cardoso CC, Auat M, Santos-Pirath IM, Rudolf-Oliveira RCM, da Silva JP, Lange BG, Siegel D, de Moraes ACR, Del Moral JAG, Santos-Silva MC.

Cytometry B Clin Cytom. 2017 May 16. doi: 10.1002/cyto.b.21533. [Epub ahead of print]

PMID:
28509416
2.

A Sequence in the loop domain of hepatitis C virus E2 protein identified in silico as crucial for the selective binding to human CD81.

Chang CC, Hsu HJ, Yen JH, Lo SY, Liou JW.

PLoS One. 2017 May 8;12(5):e0177383. doi: 10.1371/journal.pone.0177383. eCollection 2017.

3.

CD81 as a tumor target.

Vences-Catalán F, Duault C, Kuo CC, Rajapaksa R, Levy R, Levy S.

Biochem Soc Trans. 2017 Apr 15;45(2):531-535. doi: 10.1042/BST20160478. Review.

PMID:
28408492
4.

The specificity of homomeric clustering of CD81 is mediated by its δ-loop.

Homsi Y, Lang T.

FEBS Open Bio. 2017 Jan 19;7(2):274-283. doi: 10.1002/2211-5463.12187. eCollection 2017 Feb.

5.

Up-regulation of CD81 inhibits cytotrophoblast invasion and mediates maternal endothelial cell dysfunction in preeclampsia.

Shen L, Diao Z, Sun HX, Yan GJ, Wang Z, Li RT, Dai Y, Wang J, Li J, Ding H, Zhao G, Zheng M, Xue P, Liu M, Zhou Y, Hu Y.

Proc Natl Acad Sci U S A. 2017 Feb 21;114(8):1940-1945. doi: 10.1073/pnas.1617601114. Epub 2017 Feb 6.

6.

Targeting CD19: the good, the bad, and CD81.

Velasquez MP, Gottschalk S.

Blood. 2017 Jan 5;129(1):9-10. doi: 10.1182/blood-2016-11-749143. No abstract available.

7.

The CD9, CD81, and CD151 EC2 domains bind to the classical RGD-binding site of integrin αvβ3.

Yu J, Lee CY, Changou CA, Cedano-Prieto DM, Takada YK, Takada Y.

Biochem J. 2017 Feb 15;474(4):589-596. doi: 10.1042/BCJ20160998. Epub 2016 Dec 19.

PMID:
27993971
8.

Hepatitis C virus infection propagates through interactions between Syndecan-1 and CD81 and impacts the hepatocyte glycocalyx.

Grigorov B, Reungoat E, Gentil Dit Maurin A, Varbanov M, Blaising J, Michelet M, Manuel R, Parent R, Bartosch B, Zoulim F, Ruggiero F, Pécheur EI.

Cell Microbiol. 2017 May;19(5). doi: 10.1111/cmi.12711. Epub 2016 Dec 23.

PMID:
27930836
9.

Mice Expressing Minimally Humanized CD81 and Occludin Genes Support Hepatitis C Virus Uptake In Vivo.

Ding Q, von Schaewen M, Hrebikova G, Heller B, Sandmann L, Plaas M, Ploss A.

J Virol. 2017 Jan 31;91(4). pii: e01799-16. doi: 10.1128/JVI.01799-16. Print 2017 Feb 15.

PMID:
27928007
10.

Mechanism of Structural Tuning of the Hepatitis C Virus Human Cellular Receptor CD81 Large Extracellular Loop.

Cunha ES, Sfriso P, Rojas AL, Hospital A, Orozco M, Abrescia NG.

Structure. 2017 Jan 3;25(1):53-65. doi: 10.1016/j.str.2016.11.003. Epub 2016 Dec 1.

PMID:
27916518
11.

Characterization of tetraspanin protein CD81 in mouse spermatozoa and bovine gametes.

Jankovicova J, Frolikova M, Sebkova N, Simon M, Cupperova P, Lipcseyova D, Michalkova K, Horovska L, Sedlacek R, Stopka P, Antalikova J, Dvorakova-Hortova K.

Reproduction. 2016 Dec;152(6):785-793. Epub 2016 Sep 27.

PMID:
27679865
12.

Tetraspanin CD81 is an adverse prognostic marker in acute myeloid leukemia.

Boyer T, Guihard S, Roumier C, Peyrouze P, Gonzales F, Berthon C, Quesnel B, Preudhomme C, Behal H, Duhamel A, Roche-Lestienne C, Cheok M.

Oncotarget. 2016 Sep 20;7(38):62377-62385. doi: 10.18632/oncotarget.11481.

13.

Lymphocyte enrichment using CD81-targeted immunoaffinity matrix.

Pelák O, Kužílková D, Thürner D, Kiene ML, Stanar K, Stuchlý J, Vášková M, Starý J, Hrušák O, Stadler H, Kalina T.

Cytometry A. 2017 Jan;91(1):62-72. doi: 10.1002/cyto.a.22918. Epub 2016 Aug 4.

PMID:
27490854
14.

Tetraspanin CD81, a modulator of immune suppression in cancer and metastasis.

Vences-Catalán F, Rajapaksa R, Srivastava MK, Marabelle A, Kuo CC, Levy R, Levy S.

Oncoimmunology. 2015 Dec 18;5(5):e1120399. doi: 10.1080/2162402X.2015.1120399. eCollection 2016 May.

15.

Oligomerization of the Tetraspanin CD81 via the Flexibility of Its δ-Loop.

Schmidt TH, Homsi Y, Lang T.

Biophys J. 2016 Jun 7;110(11):2463-74. doi: 10.1016/j.bpj.2016.05.003.

PMID:
27276264
16.

Alirocumab, a Therapeutic Human Antibody to PCSK9, Does Not Affect CD81 Levels or Hepatitis C Virus Entry and Replication into Hepatocytes.

Ramanathan A, Gusarova V, Stahl N, Gurnett-Bander A, Kyratsous CA.

PLoS One. 2016 Apr 26;11(4):e0154498. doi: 10.1371/journal.pone.0154498. eCollection 2016.

17.

Novel impact of EWI-2, CD9, and CD81 on TGF-β signaling in melanoma.

Wang HX, Hemler ME.

Mol Cell Oncol. 2015 Oct 2;2(1). pii: e1030536. Epub 2015 Apr 15.

18.

CD81 and CD48 show different expression on blood eosinophils in systemic sclerosis: new markers for disease and pulmonary inflammation?

Wuttge DM, Andreasson A, Tufvesson E, Johansson ÅC, Scheja A, Hellmark T, Hesselstrand R, Truedsson L.

Scand J Rheumatol. 2016;45(2):107-13. doi: 10.3109/03009742.2015.1054877. Epub 2015 Nov 17.

PMID:
26926492
19.

Trachelogenin, a novel inhibitor of hepatitis C virus entry through CD81.

Qian XJ, Jin YS, Chen HS, Xu QQ, Ren H, Zhu SY, Tang HL, Wang Y, Zhao P, Qi ZT, Zhu YZ.

J Gen Virol. 2016 May;97(5):1134-44. doi: 10.1099/jgv.0.000432. Epub 2016 Feb 15.

PMID:
26879209
20.

Autoantibodies to tetraspanins (CD9, CD81 and CD82) in demyelinating diseases.

Miyaji K, Paul F, Shahrizaila N, Umapathi T, Yuki N.

J Neuroimmunol. 2016 Feb 15;291:78-81. doi: 10.1016/j.jneuroim.2015.12.012. Epub 2015 Dec 30.

PMID:
26857499

Supplemental Content

Support Center